These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 8775804)
1. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. Roberts NA AIDS; 1995 Dec; 9 Suppl 2():27-S32. PubMed ID: 8775804 [TBL] [Abstract][Full Text] [Related]
3. Protease inhibitors and prevention of cross resistance. Levin J AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875 [TBL] [Abstract][Full Text] [Related]
4. Potent new AIDS drugs underscore promise of combination therapy. AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225 [TBL] [Abstract][Full Text] [Related]
5. Update on HIV protease inhibitors. Vella S AIDS Clin Care; 1995 Oct; 7(10):79-82, 88. PubMed ID: 11362832 [TBL] [Abstract][Full Text] [Related]
6. Roche submits NDA for Invirase. J Int Assoc Physicians AIDS Care; 1995 Sep; 1(8):37-8. PubMed ID: 11362796 [TBL] [Abstract][Full Text] [Related]
7. FDA triple header. Food and Drug Administration. Smart T GMHC Treat Issues; 1995 Nov; 9(11):1-3. PubMed ID: 11362986 [TBL] [Abstract][Full Text] [Related]
8. FDA antiviral advisory hearings on lamivudine (Epivir, 3TC), saquinavir (Invirase), stavudine (Zerit, d4T), November 6-8. Food and Drug Administration. AIDS Treat News; 1995 Oct; (no 233):4-5. PubMed ID: 11363038 [TBL] [Abstract][Full Text] [Related]
9. Rational approaches to resistance: using saquinavir. Boucher C AIDS; 1996 Nov; 10 Suppl 1():S15-9. PubMed ID: 8970671 [TBL] [Abstract][Full Text] [Related]
10. No tease this time--pros and cons of a long-awaited anti-HIV drug. Chang HE Posit Aware; 1996; 7(1):18-20. PubMed ID: 11363118 [TBL] [Abstract][Full Text] [Related]
11. Ritonavir: first to prolong survival. MacDougall DS J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):38-44. PubMed ID: 11363517 [TBL] [Abstract][Full Text] [Related]
12. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. Schapiro JM; Lawrence J; Speck R; Winters MA; Efron B; Coombs RW; Collier AC; Merigan TC J Infect Dis; 1999 Jan; 179(1):249-53. PubMed ID: 9841849 [TBL] [Abstract][Full Text] [Related]
13. Conference looks at HIV drug resistance. Chang HE GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910 [TBL] [Abstract][Full Text] [Related]
14. Roche investigators say Invirase does not cause cross-resistance to other protease inhibitors. Baker R BETA; 1995 Sep; ():5. PubMed ID: 11362895 [TBL] [Abstract][Full Text] [Related]
15. Clinical experience with saquinavir. Vella S AIDS; 1995 Dec; 9 Suppl 2():S21-S25. PubMed ID: 8775803 [TBL] [Abstract][Full Text] [Related]
16. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. Jacobsen H; Hänggi M; Ott M; Duncan IB; Owen S; Andreoni M; Vella S; Mous J J Infect Dis; 1996 Jun; 173(6):1379-87. PubMed ID: 8648209 [TBL] [Abstract][Full Text] [Related]
17. Protease inhibitor trials moving to next phase. AIDS Alert; 1995 Aug; 10(8):100-1. PubMed ID: 11362675 [TBL] [Abstract][Full Text] [Related]
18. Saquinavir plus ddC reduces deaths by more than two-thirds. J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):51. PubMed ID: 11363697 [TBL] [Abstract][Full Text] [Related]
19. Protease inhibitor: Roche lottery deadline July 21. AIDS Treat News; 1995 Jul; (no 226):4-5. PubMed ID: 11362614 [TBL] [Abstract][Full Text] [Related]